Interest and feasibility of an HTLV-I vaccine;Interet et faisabilite d'un vaccin contre l'onco-retrovirus humain HTLV- I

Virologie

Volumn 3, Issue 2, 1999, Pages 123-132

  Kazanji, M ^a   De The G ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Animal model; ATL; HTLV I; TSP HAM; Vaccination

Indexed keywords

ANIMAL MODEL; ENDEMIC DISEASE; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; NEUROLOGIC DISEASE; NONHUMAN; PEPTIDE SYNTHESIS; POPULATION RESEARCH; RETROVIRUS; REVIEW; SKIN LYMPHOMA; VACCINATION; VIRUS GENOME; VIRUS ISOLATION;

EID: 0032891571     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Tajima K. The T- and B-cell malignancy study group and coauthors The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan : estimates of risk of ATL and its geographical and clinical features. Int J Cancer 1990 ; 45 : 237-43.
2. De Thé G, Bomford R An HTLV-I vaccine : why, how and for whom ? Aids Res Hum Retroviruses 1993 ; 9 : 381-6.
3. Robert-Guroff M, Weiss SH, Giron JA, et al. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an Aids endemic region. JAMA 1986 ; 255 : 3133-7.
4. Lee HH, Weiss SH, Brown LS, et al. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA. J Infect Dis 1990 ; 162 : 347-52.
5. Cantor KP, Weiss SH, Goedert JJ, Battjes RJ. HTLV-I/II seroprevalence and HIV/HTLV co-infection among US intravenous drug users. J Aids 1991 ; 4 : 460-7.
6. Chironna M, Calabro ML, Quarto M, et al. HTLV-I and HTLV-II infections in subjects at risk for HIV-I infection from southeastern Italy (apulia region). Int J Cancer 1996 ; 65 : 746-50.
7. Yoshida M, Seiki K, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 1984 ; 81 : 2534-7
8. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985 ; ii : 407-10.
9. Morgan O, Rodgers-Johnson P, Mora C, Char G. HTLV-I and polymyositis in Jamaica. Lancet 1989 ; ii : 1184-6.
10. Nishioka K, Maruyama I, Sato K, Kitajama I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989 ; i : 441.
11. Mochizuki M, Watanabe T, Yamaguchi K. HTLV-I uveitis : a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992 ; 83 : 236-9.
12. Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-I in Sjögren's syndrome. Lancet 1994 ; 344 : 1116-9.
13. Gessain A. Rétrovirus HTLV-I et HTLV-II et infections nosocomiales. In : Pozzetto B, ed. Les infections nosocomiales virales et agents transmissibles non conventionels. John Libbey Eurotext, 1999 (sous presse).
14. Bartholomew C, Blattner W, Cleghorn F. Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet 1987 ; ii : 1469.
15. Page JB, Lai S, Chitwood DD, Klimas NG, Smith PC, Fletcher MA. HTLV-I/II and death from Aids among HIV1 seropositive intravenous drug users. Lancet 1990 ; 335 : 1439-41.
16. Takahashi K, Takezaki T, Oki T, et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-Lymphotropic Virus Type I Int J Cancer 1991 ; 49 : 673-7.
17. Gessain A, Mahieux R, de Thé G. Genetic variability and molecular epidemiology of human and simian T cell leukemia/lymphoma virus type I. J Aids 1996 ; 13 (Suppl 1) : S132-45.
18. Wattel E, Cavrois M, Gessain A, Wain-Hobson S Clonal expansion of intected cells-a way of life for HTLV-1. J Aids 1996 ; 13 (Suppl 1) : S92-9.
19. Mahieux R, Ibrahim F, Mauclère P, et al. Molecular epidemiology of 58 new african human T cell leukemia virus type 1 (HTLV-1) strains : identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies. J Virol 1997 ; 71 : 1317-33.
20. Mahieux R, de Thé G, Gessain A. The tax mutation at nucleotide 7959 of human T-cell leukemia virus type 1 (HTLV-1) is not associated with tropical spastic paraparesis/HTLV-1-associated myelopathy but is linked to the cosmopolitan molecular genotype. J Virol 1995 ; 69 : 5925-7.
21. Clapham P, Nagy H, Weiss R. Pseudotypes of HTLV-I and II: neutralisation by patient's sera. Proc Natl Acad Sci 1984 ; 81 : 2886-9.
22. Nagy K, Clapham P, Cheinsong-Popov R, Weiss R. Human T-cell leukemia virus type I : induction of syncytia and inhibition by patient's sera. Int J Cancer 1983 ; 32 : 321-8.
23. Sawada T, Iwahara Y, Ishii K, Taguchi H, Hoshino H, Miyoshi I. Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits. J Inf Dis 1991 ; 164 : 1193-6.
24. Kataoka R, Takehara N, Iwahara Y. Transmission on HTLV-I by blood transfusion and its prevention by passive immunization in rabbits. Blood 1990 ; 76 : 1657-61.
25. Miyoshi I, Takehara N, Sawada T, et al. Immunoglobulin prophylaxis against HTLV-I in a rabbit model. Leukemia 1992 ; 6 : 24-6.
26. Morishita N, Ishii K, Tanaka Y, et al. Immunoglobulin prophylaxis against human T cell lymphotropic virus type II in rabbits. J Inf Dis 1994 ; 169 : 620-3.
27. Akari H, Suzuki T, Ikeda K, et al. Prophylaxis of experimental HTLV-I infection in Cynomolgus monkeys by passive immunization. Vaccine 1997 ; 15 : 1391-5.
28. Tanaka Y, Zeng L, Shiraki H, Shida H, Tozawa H. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol 1991 ; 147 : 354-60.
29. Baba E, Nakamura M, Ohkuma K, et al. A peptide-based human T cell leukemia virus type 1 vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. J Immunol 1995 ; 154 : 399-412.
30. Jacobson S, Reuben JS, Streilein RD, Palker TJ. Induction of CD4+, human T lymphotropic virus type-I-specific cytotoxic T lymphocytes from patient with HAM/TSP - recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-I. J Immunol 1991 ; 146 : 1155-62.
31. Ibrahim F, de Thé G, Gessain A. Isolation and characterization of a new simian T-cell leukemia virus type I from naturally infected Celebes macaques (Macaco ionkeana) : complete nucleotide sequence and phylogenetic relationship with the Australo-Melanesian human T-cell leukemia virus type-I. J Virol 1995 ; 69 : 6980-93.
32. Mahieux R, Chappey C, Georges-Courbot MC, et al Simian T lymphotropic virus type 1 from Mandrillus sphinx as a simian counterpart of human T cell lymphotropic virus type 1 subtype D. J Virol 1998 ; 72 : 10316-22.
33. Lairmore MD, Roberts R, Franck D, Rovnak J, Weiser MG, Cockerell GL. 1992. Comparative biological response of rabbits infected with HTLV-I isolates from patients with lymphoproliferative and neurodegenerative disease. Int J Cancer 1992 ; 50 : 124-30.
34. Miyoshi I, Yoshimoto S, Kubonishi I. Infectious transmission of human T-cell leukemia virus in rabbits. Int J Cancer 1985 ; 35 : 81-5.
35. Ishiguro N, Abe M, Seto K, et al. A rat model of human T lymphocyte virus type I (HTLV-I) infection. I. Humoral antibody response, provirus integration, and HTLV-I-associated myelopathy/tropical spastic paraparesis-like myelopathy in seronegative HTLV-I carrier rats. J Exp Med 1992 ; 176 : 981-9.
36. Suga T, Kameyama T, Kinoshita T. Infection of rats with HTLV-I : a small animal model for HTLV-I carriers. Int J Cancer 1991 ; 49 : 764-9.
37. Ibrahim F, Fiette L, Gessain A, Buisson N, de Thé G, Bomford R. Infection of rats with HTLV-I : susceptibility of inbred strains, antibody response, and provirus location. Int J Cancer 1994 ; 58 : 446-51.
38. Tateno M, Kondo N, Itoh T, Chubachi T, Togashi T, Yoshiki T. Rat lymphoid cell lines with human T cell leukemia virus production. J Exp Med 1984 ; 159 : 1105-16.
39. Kazanji M, Ibrahim F, Fiette L, Bomford R, de The G. Role of the genetic background of rats in infection by HTLV-I and in the development of associated diseases. Int J Cancer 1997 ; 73 : 131-6
40. Kushida S, Mizusawa H, Matsumura M, et al. High incidence of HAM/TSP-like symptoms in WKA rats after administration of human T-cell leukemia virus type 1-producing cells. J Virol 1994 ; 68 : 7221-6.
41. Nakamura H, Tanaka Y, Komuro-Tsujimoto A, et al. Experimental inoculation of monkeys with autologous lymphoid cell lines immortalized by and producing human T-cell leukemia virus type-I. Int J Cancer 1986 ; 38 : 867-75.
42. Yamanouchi K, Kinoshita K, Moriuchi R. Oral transmission of HTLV-I into a common marmoset as an experimental model for milkborne transmission. Gann 1985 ; 76 : 481-7.
43. Kazanji M, Moreau JP, Mahieux R, et al. HTLV-I Infection in squirrel monkeys (Saimiri sciureus) using autologous, homologous or heterologous HTLV-I-producing cell lines. Virology 1997 ; 231 : 258-66.
44. Shida H, Tochikura T, Sato T, et al Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 1987 ; 6 : 3379-84.
45. Hakoda E, Machida H, Tanaka Y, et al. Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I. Int J Cancer 1995 ; 60 : 567-70.
46. Ibuki K, Funahashi S, Yamamoto H, et al. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the HTLV-I envelope gene. J Gen Virol 1997 ; 78 : 147-52.
47. Franchini G, Tartaglia J, Markham P, et al. Highly attenuated HTLV type I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. Aids Res Hum Retroviruses 1995 ; 11 : 307-13.
48. Nakamura H, Hayami M, Ohta Y, et al. Protection of cynomolgus monkeys against infection by HTLV-I by immunization with viral env gene products produced in E coli Int J Cancer 1987 ; 40 : 403-7.
49. Arp J, Ford CM, Palker TJ, King EE, Dekaban GA Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in a baculoviras system J Gen Virol 1993 ; 74 : 211-22.
50. Tanaka Y, Tanaka R, Terada E, et al. Induction of antibody response that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. J Virol 1994 ; 68 : 6323-31.
51. Lairmore MD, DiGeorge AM, Conrad SF, et al Human T-lymphotropic virus type I peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. J Virol 1995 ; 69 : 6077-89.
52. Kazanji M, Bomfrod R, Bessereau JL, Schulz T, de Thé G. Expression and immunogenicity in rats of recombinant adenovirus 5, DNA plasmide and vaccinia viruse containing the HTLV-I env gene. Int J Cancer 1997; 71 : 300-7.
53. Ugen KE, Agadjanyan M, Wang B, et al. Elicitation of immune responses in rodents after DNA inoculation with an HTLV-I envelope glycoprotein expressing construct : a model for vaccination efficacy. Vaccines 1995 : 129-347
54. Grange MP, Armand MA, Audoly G, Thollot D, Desgranges C. Induction of neutralizing antibodies against HTLV-I envelope proteins after combined genetic protein immunization in mice. DNA & Cell Biology 1997 ; 12 : 1439-48.
55. + cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease Nature 1990 ; 348 : 245-8.
56. Bangham C, Kermode AG, Hall SE. Daenke. The cytotoxic T-lymphocyte response to HTLV-I : the main determinant of disease ? Semin Virol 1996 ; 7 : 41-8.
57. Kannagi M, Matsushita S, Shida H, Harada S. Cytotoxic T cell response and expression of the target antigen in HTLV-I infection. Leukemia 1994 ; 1 : S54-9.